ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
 PMID: 10669360       2000       The Journal of infectious diseases
Abstract: Hepatitis B virus (HBV) drug resistance to lamivudine is always accompanied by mutations in the viral polymerase gene at position 550, termed group 1 (M550V with L526M) or group 2 (M550I) mutations.


  Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those of acute hepatitis.
 PMID: 10745228       2000       Journal of medical virology
Abstract: Of note as negative data, the mutations C1653T and T1753M of the enhancer II (Enh II) and A1762T and G1764A of the precore/core promoter regions, once reported to be relevant to severe or fulminant hepatitis, were not found in the present cases.
Abstract: Remarkably, the nonsense mutation at precore codon 28 (Trp82Stop) was found in four of the five patients with fulminant hepatitis, while all the acute hepatitis patients harbored wild type (o


  Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.
 PMID: 10760047       2000       Journal of viral hepatitis
Abstract: As expected, lamivudine was much less ( approximately 200-fold) effective at inhibiting replication of the M550V mutant virus than the wild-type virus.
Abstract: Several nucleoside analogues (penciclovir, lobucavir, dioxalane guanine [DXG], 1-beta-2,6-diaminopurine dioxalane [DAPD], L-FMAU, lamivudine) and acyclic nucleoside phosphonate analogues (adefovir, tenofovir) that are in clinical use, in clinical trials or under preclinical development for the treatment of hepatitis B virus (HBV) infections, were evaluated for their inhibitory effect on the replication of a la- mivudine-resistant HBV variant containing the methionine --> valine substitution (M550V) in the polymerase nucleoside-binding domain.
Abstract: The antiviral activity was determined in the tetracycline-responsive HepAD38 and HepAD79 cells, which are stably transfected with either a cDNA copy of the wild-ty


  Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
 PMID: 10762559       2000       The Journal of infectious diseases
Abstract: No mutation in the YMDD motif was observed, whereas an L528M mutation was clearly selected by famciclovir treatment in 2 patients, as well as 14 novel mutations in 7 patients.


  Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.
 PMID: 10775637       2000       Journal of virology
Abstract: Our current study demonstrates that this abnormality can be efficiently offset by another frequent core mutation, P130T.


  [Hepatitis B virus gene mutations in the sera of three patients with coexisting hepatitis B surface antigen and anti-surface antibody].
 PMID: 10804824       2000       Rinsho byori. The Japanese journal of clinical pathology
Abstract: Case 1 possessed a point mutation, T to C at nucleotide position 1753, in the region overlapping the coding region of the X gene and the CCAAT/enhancer binding protein(C/EBP) binding region within the core promoter region.


  Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
 PMID: 10827158       2000       Hepatology (Baltimore, Md.)
Abstract: Of the 23 patients included, 13 harbored either one or a mixture of the two common YMDD-motif mutants (methionine 552-to-isoleucine [M552I] and leucine 528-to-methionine/methionine 552-to-valine [L528M/M552V]) throughout the course, whereas in the remaining 10 patients, distinct mutants became dominant over the original mutants to cause continuing chronic hepatitis.
Abstract: Of them, 3 developed an alanine 529-to-threonine (A529T) mutant, 6 developed a leucine 528-to-methionine/methionine 552-to-isoleucine (L528M


  Detection of hepatitis B virus surface antigen mutants in paraffin-embedded hepatocellular carcinoma tissues.
 PMID: 10949955       2000       Virus genes
1Abstract: Mutations on the ""a"" determinant (Thr126Ser, Gly145Arg, a double mutant Thr126Ser/Gln129Asn, Met 133Leu and Thr140Ile) were identified in 5 samples while the wild type sequence was found in 2 others."


  In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note.
 PMID: 10996115       2000       Journal of clinical virology
Abstract: Nineteen weeks later, the virus exhibited additional resistance-associated mutations (L528M and I552V).
Abstract: Significant genotypic resistance was detectable after 68 weeks, indicated by a substitution of isoleucine for methionine at residue 552 (M552I).


  Hepatitis B virus X gene variability in French-born patients with chronic hepatitis and hepatocellular carcinoma.
 PMID: 11002246       2000       Journal of medical virology
1Abstract: The changes K130M and V131I, considered as ""hot spot mutations,"" were found in strains of HCC patients carrying an ayw subtype of the HBV genome but not in the ones of chronically infected patients."



Browser Board

 Co-occurred Entities




   Filtrator